[{"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OrphoMed"},{"company":"ImmunogenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ImmunogenX"},{"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OrphoMed"},{"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OrphoMed"},{"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Oragenics"},{"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OrphoMed"},{"company":"ColonaryConcepts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2B Study of ColonaryConcepts\u2019 Novel Colonoscopy Prep Confirms Excellent Efficacy & Safety Higher Patient Preference Over Standard Prep","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"ColonaryConcepts"},{"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces First Patient Dosed in Phase 2 Study of Oral AMT-101 in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Applied Molecular Transport"},{"company":"Synthetic Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Synthetic Biologics"},{"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Gossamer Bio"},{"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of AMT-101 for Inflammatory Diseases in The Journal of Immunology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Applied Molecular Transport"},{"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Publishes Positive SER-287 Phase 1B Ulcerative Colitis Study Results in Journal Gastroenterology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Seres Therapeutics"},{"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"OrphoMed"},{"company":"Ventyx Biosciences","sponsor":"venBio","pharmaFlowCategory":"D","amount":"$114.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ventyx Biosciences"},{"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2B ECO-Reset Study for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Seres Therapeutics"},{"company":"Parexel Biotech","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InDex Pharmaceuticals Enters Agreement with Parexel Biotech for Phase III Clinical Study of Cobitolimod for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Parexel Biotech"},{"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed\u2019s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"OrphoMed"},{"company":"Seed Health","sponsor":"The Craftory","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Seed Health"},{"company":"Palisade Bio","sponsor":"Palisade Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leading BioSciences Closes Merger with Seneca Biopharma and Set to Begin Trading on Nasdaq as PALI","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"},{"company":"Duke Clinical Research Institute","sponsor":"9 Meters Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"9 Meters Biopharma Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Duke Clinical Research Institute"},{"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight for Late-Stage Clinical Trials of LB1148","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"},{"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$218.0 million","upfrontCash":"$18.0 million","newsHeadline":"Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement for Omilancor and NX-13","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Landos Biopharma"},{"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landos Phase 2 Data of Omilancor in Ulcerative Colitisr Oral Presentation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Landos Biopharma"},{"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Seres Therapeutics"},{"company":"Palisade Bio","sponsor":"Yuma Regional Medical Center","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Announces $5.2M Investment by The Yuma Regional Medical Center","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"},{"company":"Landos Biopharma","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn\u2019s Disease with the Icahn School of Medicine at Mount Sinai","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Landos Biopharma"},{"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Bristol Myers Squibb"},{"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Applied Molecular Transport"},{"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Prometheus Biosciences"},{"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Peptide","graph2":"9 Meters Biopharma"},{"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of \u20181104 in Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Revolo Biotherapeutics"},{"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"},{"company":"Janssen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Vers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Janssen Pharmaceutical"},{"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"},{"company":"Adiso Therapeutics","sponsor":"Morning side VENTURE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morningside Ventures Launches Adiso Therapeutics to Advance Novel Therapies for Inflammatory Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Adiso Therapeutics"},{"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Morphic Therapeutic"},{"company":"Concentric Analgesics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concentric Analgesics Announces Positive Results from Pilot Phase 2 Clinical Trial of Vocacapsaicin in Open Laparotomy for Repair of Abdominal Ventral Hernia","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Concentric Analgesics"},{"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Receives FDA Study May Proceed Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"},{"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Protagonist Therapeutics"},{"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Gossamer Bio"},{"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Citius Pharmaceuticals"},{"company":"Palisade Bio","sponsor":"Newsoara","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Palisade Bio"},{"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Anji Pharmaceutical"},{"company":"EpicentRx","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpicentRx Announces Poster Presentation for Phase 2 Randomized Clinical Trial with RRx-001 as an Anti-Mucositis Agent in Locally Advanced Head and Neck Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"EpicentRx"},{"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Immunic Therapeutics"},{"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Prometheus Biosciences"},{"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Applied Molecular Transport"},{"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Prometheus Biosciences"},{"company":"ImmunogenX","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"ImmunogenX"},{"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Peptide","graph2":"9 Meters Biopharma"},{"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Palatin Technologies"},{"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Allakos"},{"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Applied Molecular Transport"}]
Details:
AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in Phase 2 clinical trials for chronic pouchitis, UC and RA.
Lead Product(s):
AMT-101
Therapeutic Area: Gastroenterology
Product Name: AMT-101
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 20, 2022
Details:
AK002 (Lirentelimab) selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response.
Lead Product(s):
Lirentelimab
Therapeutic Area: Gastroenterology
Product Name: AK002
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 12, 2022
Details:
PL8177 is a synthetic cyclic heptapeptide with demonstrated efficacy in multiple animal inflammatory bowel disease models. PL8177 is a potent, selective agonist at the human melanocortin receptor-1 (MC1r), with sub-nanomolar affinity binding and EC50 functional values.
Lead Product(s):
PL8177
Therapeutic Area: Gastroenterology
Product Name: PL8177
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 08, 2022
Details:
NM-002 (vurolenatide) is long-acting injectable GLP-1 receptor agonist that utilizes XTEN® technology to extend its circulating half-life. GLP-1, often referred to "ileal brake", is hormone that slows transit of food and fluid through stomach and upper intestine following meal.
Lead Product(s):
Vurolenatide
Therapeutic Area: Gastroenterology
Product Name: NM-002
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 01, 2022
Details:
The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patient.
Lead Product(s):
Latiglutenase
Therapeutic Area: Gastroenterology
Product Name: IMGX003
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Mayo Clinic
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 12, 2022
Details:
PRA023, is a monoclonal antibody against cytokine TL1A, a target associated with both intestinal inflammation and fibrosis,for the treatment of Ulcerative Colitis.
Lead Product(s):
PRA023
Therapeutic Area: Gastroenterology
Product Name: PRA023
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 18, 2022
Details:
AMT-101 is a novel, GI-selective, investigational oral recombinant biologic fusion protein of human interleukin 10 (hIL-10), an anti-inflammatory cytokine, in development for the treatment of inflammatory bowel diseases and systemic inflammatory indications.
Lead Product(s):
AMT-101,Adalimumab
Therapeutic Area: Gastroenterology
Product Name: AMT-101
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 05, 2022
Details:
PRA023 is an IgG1 humanized mAB block TNF-like ligand 1A, binds both soluble and membrane-associated human TL1A with high affinity and specificity and has potential to substantially improve outcomes for IBD patients predisposed to increased TL1A expression.
Lead Product(s):
PRA023
Therapeutic Area: Gastroenterology
Product Name: PRA023
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 08, 2022
Details:
The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of IMU-838 (vidofludimus calcium) versus placebo at week 10.
Lead Product(s):
Vidofludimus calcium anhydrous
Therapeutic Area: Gastroenterology
Product Name: IMU-838
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 02, 2022
Details:
RRx-001 leads EpicentRx's CyNRGY platform as a first-in-class investigational treatment sourced from an exclusively licensed portfolio of aerospace-derived small molecules.
Lead Product(s):
RRx-001,Cisplatin
Therapeutic Area: Gastroenterology
Product Name: RRx-001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Dana-Farber Cancer Institute
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 01, 2022
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
